Related Experiment Videos
Fenofibrate-induced acute cholestatic hepatitis.
Chiu-Yung Ho1, Tzong-Haur Kuo, Tseng-Shing Chen
1Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|September 11, 2004
Summary
Fenofibrate can rarely cause acute cholestatic hepatitis. Monitoring liver function tests is recommended after starting this medication to detect potential liver injury early.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Fenofibrate is a commonly prescribed lipid-lowering agent.
- Drug-induced liver injury (DILI) from fenofibrate is rare, with limited case reports globally.
Observation:
- A 61-year-old male developed acute cholestatic hepatitis after 10 days of fenofibrate therapy.
- Elevated liver enzymes (bilirubin, ALT, AST, ALP, GGT) and pathological findings of hepatocanalicular cholestasis were observed.
Findings:
- The patient's liver function normalized within 2 months after fenofibrate discontinuation.
- This case represents the first reported instance of fenofibrate-induced acute cholestatic hepatitis in Taiwan.
Implications:
- Routine monitoring of liver function tests is crucial within the first two weeks of fenofibrate therapy.
- Discontinuation of fenofibrate is recommended if alanine aminotransferase levels rise by over 100 IU/L to prevent severe liver damage.